declares having received consulting honoraria from Novo Nordisk, Eli Lilly, Boehringer Ingelheim and AstraZeneca, and received research grants through his affiliation from Novo Nordisk, Eli Lilly, Boehringer Ingelheim and Rhythm
For all of the concomitant medications evaluated in this study, the ratio for total exposure (AUC) was within the pre-specified limits (0.801.25), suggesting that there are no drugdrug interactions between semaglutide and the co-administered drugs
In addition, carrying less weight may reduce pain during intercourse
The work was supported by Novo Nordisk Pharma, and several authors reported financial relationships with Novo Nordisk or employment/shareholdings with the company
GLP-1 receptor agonists mimic some of its activity